Cat. No. | Product Name | Field of Application | Chemical Structure |
---|---|---|---|
DC70166 | AB-452 |
AB-452 (AB452) is a potent, small molecule inhibitor of noncanonical poly(A) polymerases PAPD5 and PAPD7 (PAPD5/7), inhibits PAPD5/7 enzymatic activities, reduces HBsAg in vitro (EC50=1.4/6.8 nM).AB-452 demonstrated specific antiviral activity for HBV, was inactive against a panel of 10 different RNA and DNA viruses with EC50 values of >30 uM.AB-452 reduced HBsAg, HBeAg, and HBV DNA production with EC50 of 0.28-6.8 nM, without cytotoxicity.AB-452 interferes with multiple steps of HBV life cycle by reducing HBV RNA.AB-452 demonstrated antiviral activity in AAV-HBV-transduced mouse model.AB-452 promotes HBV RNA degradation through inhibiting PAPD5 and PAPD7 enzymatic activities and blockage of guanosine incorporation into viral RNA poly(A) tails..
More description
|
![]() |
DC49479 | HBV-IN-14 |
HBV-IN-14 is a potent inhibitor of covalently closed circular DNA (cccDNA). cccDNA serves as the template for viral RNA transcription and subsequent viral DNA generation. HBV-IN-14 is a pyridinopyrimidinones compound. HBV-IN-14 has the potential for the research of HBV infection (extracted from patent WO2021190502A1, compound 5).
More description
|
![]() |
DC49478 | HBV-IN-16 |
HBV-IN-16 is a potent inhibitor of covalently closed circular DNA (cccDNA). cccDNA serves as the template for viral RNA transcription and subsequent viral DNA generation. HBV-IN-16 is a quinoline derivative. HBV-IN-16 has the potential for the research of HBV infection (extracted from patent WO2019121357A1, compound 1).
More description
|
![]() |
DC49477 | SHR5133 |
SHR5133 is a highly potent, orally active HBV capsid assembly modulator. SHR5133 displays HBV DNA reduction (EC50=26.6 nM).
More description
|
![]() |
DC49476 | HBV-IN-17 |
HBV-IN-17 (compound 8) is a potent HBV capsid assembly modulator with an EC50 of 511 nM.
More description
|
![]() |
DC49475 | BA38017 |
BA38017 is a potent HBV core protein assembly modulator. BA38017 inhibits HBV replication with an EC50 of 0.20 μM.
More description
|
![]() |
DC49059 | TLR8 agonist 4 |
TLR8 agonist 4 showed effective inhibition on wild-type and drug-resistant (lamivudine and entecavir) HBV strains. The IC50 values are 0.15 and 0.10 respectively μM.
More description
|
![]() |
DC48910 | HBV-IN-12 |
HBV-IN-12 is a potent hepatitis B surface antigen (HBsAg) inhibitor (0.001 μM< EC50 ≤0.05 μM). HBV-IN-12 shows anti-HBV DNA activity (0.001 μM<EC50 ≤0.02 μM). From patent WO2021204252A1, compound 15.
More description
|
![]() |
DC48901 | HBV-IN-10 |
HBV-IN-10 is an enantiomer of compound 6 (WO2021204258A1). Compound 6 is a hepatitis B surface antigen (HBsAg) inhibitor (0.001 μM< EC50 ≤0.05 μM). From patent WO2021204258A1, compound 6.
More description
|
![]() |
DC48900 | (5S,8R)-HBV-IN-10 |
(5S,8R)-HBV-IN-10 is an enantiomer of compound 6 (WO2021204258A1). Compound 6 is a hepatitis B surface antigen (HBsAg) inhibitor (0.001 μM< EC50 ≤0.05 μM). From patent WO2021204258A1, compound 6.
More description
|
![]() |
DC48892 | HBV-IN-6 |
HBV-IN-6 is a potent HBV inhibitor with an EC50 of 44 nM (WO2021213445A1, compound 3).
More description
|
![]() |
DC48865 | HBV-IN-13 |
HBV-IN-12 is a potent hepatitis B surface antigen (HBsAg) inhibitor. From patent WO2021204252A1, compound 1_B.
More description
|
![]() |
DC48862 | HBV-IN-9 |
HBV-IN-9 is a potent HBsAg (HBV Surface antigen) inhibitor (IC50=10 nM) and HBV DNA production inhibitor (IC50=0.15 nM in HepG2.2.15 cells). From patent WO2018001952A1, example 20.
More description
|
![]() |
DC48835 | HBV-IN-8 |
HBV-IN-8 is a potent HBV inhibitor with an EC50 of 287.9 nM (WO2021213445A1, compound 13).
More description
|
![]() |
DC48833 | HBV-IN-11 |
HBV-IN-11 is a potent HBsAg secretion inhibitor with an EC50 of 0.46 µM (From patent WO2018085619A1, example 28).
More description
|
![]() |
DC48709 | HBV-IN-7 |
HBV-IN-7 is a potent HBV inhibitor with an EC50 of 7 nM (WO2021213445A1, compound 5).
More description
|
![]() |
DC47304 | AB-729 |
AB-729, a nucleoside analogue, is an RNA interference (RNAi). AB-729 conjugates to a trimer of N-acetylgalactosamine (GalNAc) ligand that promotes uptake into hepatocytes via the asialoglycoprotein receptor (ASGR). AB-729 inhibits viral replication and reduces HBV antigens.
More description
|
![]() |
DC47248 | Vebicorvir |
Vebicorvir (ABI-H0731) is a first-generation hepatitis B virus (HBV) core protein inhibitor. Vebicorvir (ABI-H0731) suppresses covalently closed circular DNA (cccDNA) formation in two de novo infection models with EC50s from 1.84 μM to 7.3 μM.
More description
|
![]() |
DC47052 | Tenofovir amibufenamide |
Tenofovir amibufenamide (HS-10234), a Tenofovir prodrug, is an orally active antiviral agent. Tenofovir amibufenamide inhibits HBV, and can be used for chronic hepatitis B (CHB) study.
More description
|
![]() |
DC47037 | Firzacorvir |
Firzacorvir is a cyclic sulfamide compound and modulates HBV core protein. Firzacorvir has anti-HBV activity with EC50 < 1 μΜ.
More description
|
![]() |
DC45956 | LPRP-Et-97543 |
LPRP-Et-97543 is a potent anti-HBV agent. LPRP-Et-97543 reduces Core, S, and preS but not X promoter activities. LPRP-Et-97543 can be used for acute and chronic HBV infections research.
More description
|
![]() |
DC45517 | Schisanwilsonin C |
Schisanwilsonin C (Arisanschinin K) shows anti-HBV activity.
More description
|
![]() |
DC45405 | Chamaechromone |
Chamaechromone is a biflavonoid ingredient isolated from the roots of Stellera chamaejasme L. (Thymelaeaceae). Chamaechromone possesses anti-hepatitis B virus (HBV) effects against the surface antigen of HBV (HBsAg) secretion and has insecticidal activities.
More description
|
![]() |
DC53050 | ATI-2173 Featured |
ATI-2173 is a novel liver-targeted molecule designed to deliver the 5′-monophosphate of clevudine for the treatment of chronic hepatitis B infection.
More description
|
![]() |
DC44116 | HBV-IN-4 |
HBV-IN-4, a phthalazinone derivative, is a potent and orally active HBV DNA replication inhibitor with an IC50 of 14 nM. HBV-IN-4 induces the formation of genome-free capsids and has potent anti-HBV potencies.
More description
|
![]() |
DC40060 | LB80317 |
LB80317 is an active metabolite of LB80380 and suppresses the DNA synthesis of HBV with an EC50 of 0.5 μM. LB80317 has antiviral effect and has the potential for chronic hepatitis B treatment.
More description
|
![]() |
DC42271 | Sophoranol |
Sophoranol is an alkaloid that can be isolated from S. flavescens, with antiviral activity. Sophoranol has anti-HBV (hepatitis B virus) activity. Sophoranol shows potent antiviral activities against respiratory syncytial virus (RSV) with an IC50 of 10.4 μg/mL.
More description
|
![]() |
DC29071 | Adefovir |
Adefovir (GS-0393) is an adenosine monophosphate analog antiviral agent that after intracellular conversion to Adefovir diphosphate inhibits HBV DNA polymerase. Adefovir has an IC50 of 0.7 μM against HBV in the HepG2.2.15 cell line. Adefovir has good antiviral activity against several viruses, including HBV and herpesviruses.
More description
|
![]() |
DC11259 | NTCP binder peptide WL4 |
NTCP binder peptide WL4 is a macrocyclic peptide, pan-genotypic inhibitor of HBV cellular entry via targeting the cell-surface receptor for HBV, sodium taurocholate cotransporting polypeptide (NTCP, Kd=42 nM), reduces HBs antigen levels in culture supernatants with IC50 of 0.66 uM.
More description
|
![]() |
DC11260 | NTCP binder peptide WD1 |
NTCP binder peptide WD1 is a macrocyclic peptide, pan-genotypic inhibitor of HBV cellular entry via targeting the cell-surface receptor for HBV, sodium taurocholate cotransporting polypeptide (NTCP, Kd=15 nM), reduces HBs antigen levels in culture supernatants.
More description
|
![]() |